Rapport Therapeutics Inc
(RAPP)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||
| Net Income | -78,307 | -34,786 | -10,652 |
| Depreciation Amortization | -2,372 | 37 | 15 |
| Accounts payable and accrued liabilities | -346 | 856 | 1,445 |
| Other Working Capital | -2,416 | 2,652 | 1,488 |
| Other Operating Activity | 18,613 | 4,060 | 4,462 |
| Operating Cash Flow | $-64,828 | $-27,181 | $-3,242 |
| Cash Flows From Investing Activities | |||
| Change In Deposits | -167,736 | -77,224 | N/A |
| PPE Investments | -2,405 | -1,636 | -284 |
| Purchase Sale Intangibles | N/A | N/A | -5,000 |
| Other Investing Activity | 0 | 0 | -5,000 |
| Investing Cash Flow | $-170,141 | $-78,860 | $-5,284 |
| Cash Flows From Financing Activities | |||
| Debt Issued | N/A | N/A | 8,000 |
| Common Stock Issued | 157,712 | 54 | 31 |
| Common Stock Repurchased | N/A | -4 | N/A |
| Other Financing Activity | 63,913 | 145,086 | 31,654 |
| Financing Cash Flow | $221,625 | $145,136 | $39,685 |
| Beginning Cash Position | 70,254 | 31,159 | N/A |
| End Cash Position | 56,910 | 70,254 | 31,159 |
| Net Cash Flow | $-13,344 | $39,095 | $31,159 |
| Free Cash Flow | |||
| Operating Cash Flow | -64,828 | -27,181 | -3,242 |
| Capital Expenditure | -2,405 | -1,636 | -284 |
| Free Cash Flow | -67,233 | -28,817 | -3,526 |